Capsugel Acquisition Boosts Dosage Form Solutions

September 9, 2013

The deal adds advanced bioavailability technology capabilities and new product development options.

Capsugel (Morristown, NJ) has added the bioavailability-enhancing expertise of Bend Research (Bend, OR), to its Dosage Form Solutions (DFS) business unit. Bend Research’s forte is Spray-Dried Dispersion (SDD) formulation technology and its core competencies are rooted in solutions for modified and targeted release, inhalation delivery, and biotherapeutic processing and formulation.

With a nod to the consumer penchant for formulation innovation and increased speed to market, Amit Patel, president, Capsugel DFS, said the acquisition would support “effective and accelerated product development needs from formulation feasibility to final commercial production through new and expanding technologies and capabilities.”

Rod Ray, Ph.D., CEO of Bend Research, added that the deal would enable Bend to broaden its handle on new bioavailability formulation challenges, increase its global reach, and grow its ability to scale-up and commercially manufacture the customer compounds it helps formulate.

The terms of the deal were not disclosed.